Table 1 Baseline characteristics of the prospective RA patient cohort
Baseline variable | Total (n = 80) | Responders (n = 67) | Non-Responders (n = 13) |
|---|---|---|---|
Age, years (mean ± SD) | 54.2 ± 11.93 | 53.12 ± 11.65 | 59.7 ± 12.32 |
Gender (Female,n %) | 66 (82.5) | 54 (80.6) | 12 (92) |
Previous csDMARDs (mean ± SD) | 1.85 ± 1.28 | 1.82 ± 1.24 | 2 ± 1.53 |
Disease duration, years (median/IQR) | 9.74 (9.25) | 9.24 (9.5) | 12.31 (11.41) |
ESR, mm/h (median/IQR) | 35.1 (28.75) | 36.52 (34) | 27.7 (21.17) |
CRP, mg/dL (median/IQR) | 1.63 (1.27) | 1.63 (1.23) | 1.62 (1.47) |
MTX dosage (mean mg/week) | 18.46 | 18.25 | 19.64 |
Prednisone use (n, %) | 60 (75) | 50 (74.6) | 10 (77) |
Smoking (n, %) | |||
Never | 54 (67.5) | 44 (65.7) | 10 (77) |
Past | 10 (12.5) | 6 (9) | 3 (23) |
Current | 16 (20) | 17 (25.3) | 0 (0) |
Adalimumab | 16 (20) | 15 (22.4) | 1 (8) |
Certolizumab | 24 (30) | 21 (31.3) | 3 (23) |
Etanercept | 19 (23.75) | 16 (23.4) | 3 (23) |
Golimumab | 21 (26.25) | 15 (22.4) | 6 (46) |